Title

Penicillin Allergy as an Instrumental Variable for Estimating Antibiotic Effects
on Resistance

Authors List

Yaki Saciuk MPH[1,2], Daniel Nevo PhD[3], Michal Chowers MD[4,5*], Uri Obolski PhD[1*]

Affiliations

* Corresponding author: Uri Obolski; uriobols@tauex.tau.ac.il
Tel Aviv University, Chaim Levanon St 55, Tel Aviv-Yafo, 6997801
10
11 * Corresponding author: Michal Chowers; chowersm@tauex.tau.ac.il
12 Tel Aviv University, Chaim Levanon St 55, Tel Aviv-Yafo, 6997801
13
14 Corresponding authors jointly supervised this study
15
16
17
[1]Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of
Medical & Health Sciences Tel Aviv University, Tel Aviv, Israel.
[2] Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel
Aviv, Israel.
[3] Department of Statistics and Operations Research, Faculty of Exact Sciences, Tel Aviv
University, Tel Aviv, Israel.
[4]Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
[5]Meir Medical Center, Kfar Saba, Israel.
26
27 Yaki Saciuk: saciuk_y@mac.org.il
28 Daniel Nevo: danielnevo@tauex.tau.ac.il

Abstract

Antibiotic resistance is influenced by prior antibiotic use, but precise causal estimates are limited. This study uses penicillin allergy as an instrumental variable (IV) to estimate the causal effect of antibiotics on resistance. A retrospective cohort of 36,351 individuals with *E. coli* positive urine cultures and prior outpatient antibiotic use, with outcomes assessed up to one year post-exposure, was analyzed using data from Maccabi Healthcare Services (MHS), the second-largest non-profit health fund in Israel. IV methods estimated risk differences (RD) and numbers needed to harm (NNH) for penicillin versus other antibiotics. The RD for resistance was 11.4% (95% CI: 7.6%, 15.4%) for amoxicillin/clavulanic acid, 14.1% (95% CI: 9.0%, 19.4%) for ampicillin, and 0.8% (95% CI: 0.2%, 1.4%) for piperacillin/tazobactam, with NNHs of 8.8, 7.1, and 122.0, respectively. Risks declined over time since exposure. Gentamicin, used as a negative control, showed no effect (95% CI: -2.4%, 1.8%). When directly comparing penicillin and quinolone effects on their respective AMR, penicillin use within 180 days increased resistance to amoxicillin/clavulanic acid by an RD of 17.8% (95% CI: 2.1%, 35.2%; NNH: 5.6), while quinolones raised ciprofloxacin resistance by 43.7% (95% CI: 29.9%, 59.4%; NNH: 2.3). These findings provide quantitative evidence of the impact of prior penicillin use on resistance, with implications for clinical practice and prescription policies.

Introduction

Antibiotics are vital in combating bacterial infections, yet their effectiveness is diminishing due to increased antimicrobial resistance (AMR), partly stemming from overuse and misuse [1,2]. The susceptibility of an infection to antibiotics is typically determined through microbiological testing, a process that can take several days. Consequently, a common scenario contributing to antibiotic misuse arises when patients are treated with antibiotics before the causative pathogen and its AMR profile are identified—an approach known as empiric therapy. Once antibiotic susceptibility results are available, they are reported as minimum inhibitory concentrations (MICs)—the minimum concentration of an antibiotic required to inhibit the growth of the pathogen—or categorized into susceptible, intermediate, or resistant groups based on established MIC thresholds[3]. To enhance responsible prescription of antibiotics, guidelines have been developed

that facilitate treatment decisions based on anticipated pathogens, resistance profiles, and related

healthcare costs of different antibiotics[3].

AMR arises from both individual and population-level antibiotic use [4]. At the population-level,

the overall volume and patterns of antibiotic play a significant role in driving resistance, as resistant

pathogens spread between individuals [4,5]. At the individual level, antibiotic use selects for infection

and colonization with resistant bacterial strains [5,6]. In recent years, there has been a growing focus

on the potential of different antibiotics to induce future resistance on an individual-level. For

example, quinolones, previously the primary choice for urinary tract infections and community-

acquired pneumonia, are now often disfavored due to their high potential for resistance induction[7].

Nonetheless, a significant gap in current research is the lack of quantitative, causal assessments

of the risk of future resistance caused by different antibiotics. Randomized control trials, the

benchmark for causal effect estimation, present logistical difficulties in this context, including

limited patient follow up and the requirement for numerous studies to address various clinical

scenarios and antibiotic combinations. Consequently, ranking of antibiotics by their collateral

resistance cost is often reached by expert opinion [8–10]. Alternatively, cohort studies aimed at

evaluating the effects of antibiotics are susceptible to numerous confounding mechanisms that

undermine the causal validity of their results[5,11].

Potential confounders, such as the indication for antibiotic use, illness severity at presentation, and

patient demographics, present substantial challenges for retrospective studies in this field;

researchers often struggle to access these variables. However, advances in causal inference theory

have substantially improved our ability to discern causal effects from observational data. In

particular, the use of instrumental variables (IVs) can provide reliable estimates of causal effects,

when the appropriate methodology and falsification tests are applied [12,13], emulating natural-

experiment-like conditions.

Here, we propose to employ reported allergy to penicillin as such an IV. Reported penicillin allergy

satisfies the essential conditions needed for a valid IV analysis. First, it causally influences

prescription practices[14], leading physicians to opt for non-penicillin antibiotics upon presentation

of penicillin allergy. Second, reported penicillin allergy also inherently does not directly affect

AMR of bacterial populations.

By controlling for measured covariates which have the potential to confound the relationship
between the IV (allergy to penicillin) and the outcome (AMR), we can further bolster the
assumption of the causal nature of this association. Moreover, the setting of antibiotic
susceptibility testing provides a falsification test for this assumption. We can utilize resistance to
antibiotics outside the penicillin group as a negative control outcome (NCO) [13,15,16], which could
offer additional support for the validity of this assumption. The essential causal relationships
assumed in our study are concisely depicted in the directed acyclic graph (DAG)[17] in Figure 1.

In this study, we utilize a large and comprehensive medical records database and leverage IV
analysis to estimate the effects of consumption of penicillins, compared to other antibiotics, on
AMR in subsequent bacterial cultures. Specifically, we estimate the Risk Difference (RD) and
Number Needed to Harm (NNH) of AMR in *E. coli*. We further estimate the effects of antibiotic
consumption on AMR over different time periods following antibiotic use. To do this, we adjust
for multiple variables to eliminate potential IV-outcome confounding and apply inverse probability
of censoring weighting (IPCW) to mitigate selection bias. Finally, we perform negative control
analyses to ascertain the validity of our IV.
111

112 **Results**

113
Within the primary research population, encompassing 1,469,624 individuals who received at least
one outpatient antibiotic prescription from January 2013 to December 2022, a subset of 36,351
individuals underwent at least one AMR test panel within a following 12-month period. In total,
41,647 AMR test panels were administered. The distribution of patient characteristics and
selection criteria for the research population are further illustrated in Figure 2, with detailed patient
characteristics provided in Table 1. To verify the IV Relevance condition, we computed the first-
stage adjusted OLS regression, which yielded significant Kleibergen-Paap F-statistics and IV
coefficients of approximately 23%, indicating a strong link between the IV and the exposure (Table
S1).
We analyzed varying post-exposure follow-up times for two main reasons. First, the impact of
antibiotic exposure on AMR diminishes over time as the perturbation to the patient's microbiome
subsides, with most associations likely decaying after a year[6,18], making estimates at different time
points valuable. Second, identifying this time-dependent effect (or its absence, in the NCO) further

validates our analyses. In the initial up to 90 days post-exposure, penicillin users exhibited
significantly higher RDs for AMR within the penicillin group compared to other treatments.
Specifically, resistance to amoxicillin/clavulanic acid, ampicillin, and piperacillin/tazobactam
exhibited RDs of 19.0% (95% CI: 11.8%, 26.1%), 22.6% (95% CI: 14.6%, 31.0%), and 2.5% (95%
CI: 1.4%, 3.5%), respectively. The corresponding NNH values were 5.3, 4.4, and 40.2 (Table 2).
These RDs consistently remained statistically significant across various post-exposure outcome
time points and exhibited a temporal decline, aligning with expected AMR reduction as time
elapsed. In contrast, gentamicin's RD, serving as a negative control, was close to zero and remained
statistically non-significant at all time points and did not show a decreasing trend in the RD point
estimate (Figure 3). It is worth emphasizing that the estimate within each interval encapsulates a
weighted average of the RD over the entire period, rather than an RD estimated at a specific time
point.
We conducted several sensitivity analyses to ascertain the robustness of our results. First, the
presented results incorporate IPCW adjustments, and unweighted analyses, exhibiting similar
results, are available in Table S2 for comparison. Second, although adjusted for in the primary
analysis, the socio-demographic differences between penicillin-allergic and non-allergic groups
could potentially affect the validity of the results. To address this concern, we conducted sensitivity
analyses using full matching [19,20] on covariates and replaced the standard linear model with a
probit model in the first stage of the 2SLS procedure[21]. The results again largely corroborated our
original findings (Table S3).
Finally, to address the composition of the penicillin group, we repeated our original analysis while
limiting the exposure to either amoxicillin/clavulanic acid, amoxicillin, or amoxicillin with other
penicillins. The consistent results from this analysis are displayed in Table S4.
We then directly compared the effects of penicillin and quinolone exposure on AMR, focusing on
a 180-day follow-up period. This follow-up duration was chosen to balance the trade-off between
effect size and sample size, as the subgroup sizes became smaller for longer follow-up periods. To
evaluate quinolone resistance, we analyzed susceptibility results for ciprofloxacin, a commonly
tested-for-resistance quinolone within Maccabi Healthcare Services (MHS). The findings,
summarized in Table 3 and Figure 4, indicate prior penicillin use increases resistance, relative to
prior fluoroquinolone use in three penicillin antibiotics, albeit the ampicillin resistance outcome
was not statistically significant. Conversely, prior quinolone exposure, relative to penicillin

exposure, presented a pronounced influence on subsequent quinolone resistance (with a negative
RD due to quinolones being the control group). The RD for amoxicillin/clavulanic acid was 17.8%
(95% CI: 2.1%, 35.2%), for ampicillin 8.0% (95% CI: -5.3%, 22.6%), for piperacillin/tazobactam
2.8% (95% CI: 0.9%, 4.6%), for gentamicin -5.4% (95% CI: -14.6%, 2.8%), and for ciprofloxacin
-43.9% (95% CI: -59.4%, -29.9%).

We conducted pairwise comparisons between penicillin and each antibiotic group within the
control arm, excluding quinolones, aminoglycosides, and other beta-lactams, within the 180-day
window post-exposure (Table S5). The RDs varied somewhat. Comparisons with cephalosporins,
another beta-lactam, yielded statistically insignificant RDs for penicillins. Similarly, comparisons
of penicillins versus other groups for gentamicin AMR also yielded statistically insignificant RDs.

Discussion

170
This study exploits a unique phenomenon, namely purported penicillin allergy, to estimate the
causal effects of prior antibiotic use on antibiotic resistance, in real-world primary care settings.
Our analysis quantifies the impact of previous use of penicillins on resistance rates of future
infections to the three penicillins. The largest effect was observed in resistance to ampicillin,
followed by amoxicillin/clavulanic acid, and finally piperacillin/tazobactam. The low NNH values
estimated for amoxicillin/clavulanic acid and ampicillin suggest that consumption of penicillins
may frequently lead to AMR to these antibiotics upon infections. In contrast, the higher NNH for
piperacillin/tazobactam indicates a comparatively lower cost of resistance, suggesting that only a
small number of patients exposed to penicillins would lose the ability to be effectively treated with
this antibiotic due to resistance.
In line with both biological reasoning and previous knowledge, all three outcomes demonstrated a
gradual decrease in the RD for antibiotic resistance with each subsequent time point, reflecting the
diminishing impact of prior antibiotic use [18]. In contrast, gentamicin, the negative-control
antibiotic, displayed no such effect nor trend, further affirming the validity of our analysis. In our
additional analysis, we compared past usage of penicillin with that of quinolones on corresponding
AMR tests within the 180-day post-exposure. The past use of penicillins was linked to resistance
rates for penicillins; but this association was lower than the association between past use of

quinolones, and higher resistance to ciprofloxacin. This finding is consistent with previous
evidence that quinolones usage leads to substantial increase in resistance [18,22–24]. However, the
current study provides an unbiased, causally justified comparison between the antibiotic classes.
191
As with any study attempting to infer causality from observational data, this study has its
limitations. The IV analysis performed here requires several specific assumptions. The Relevance
condition has been confirmed through the coefficients obtained from the first-stage regression
models. With respect to the Independence condition, Table 1 contrasts differences in demographic
characteristics between individuals with and without a penicillin allergy. While the differences are
not pronounced, they are present: the allergic population is predominantly female, older, and of
higher socioeconomic status, suggesting a possible behavioral rather than biological basis for the
reporting of penicillin allergy [25]. The integrity of this condition was kept by adjusting for these
variables. Moreover, the near-zero effect observed in the NCO, and the lack of temporal trend,
further reassures that this condition is maintained.

To estimate the average treatment effect using IVs, we assume that treatment effects are constant
across the population. If this assumption is violated, the estimated effect can still be interpreted if
the Monotonicity assumption holds[12]. This assumption, also known as the *no defiers* assumption,
means that no individual will consistently choose a treatment contrary to their IV assignment. In
our study, it implies that individuals who would receive penicillin if not allergic would also avoid
it if allergic. Under this assumption and additional statistical assumptions, the estimated effect is
an average of Complier Average Causal Effects (CACEs) or Local Average Treatment Effects
(LATEs)[12]. The CACE/LATE represents the impact on individuals who comply with the treatment
indicated by the IV, known as *compliers*.

The study's final limitation concerns the generalizability of its estimated effects. We used a
comprehensive dataset that well-represents antimicrobial resistance of *E. coli* urine isolates in
Israel. However, the study outcomes are likely influenced by the local variations in resistance
patterns of pathogens during the period and location of the study (Figure S1). This is a common
occurrence in infectious diseases, the dynamics of which are dictated by local biological and
behavioral factors. Furthermore, our inclusion criteria, which excluded individuals who had
purchased antibiotics or been hospitalized within the previous 12 months, may have resulted in a

somewhat healthier-than-average sample, potentially limiting generalizability to other
populations. Nevertheless, our study also provides researchers with a novel approach and detailed
methodology to estimate the effects of antibiotic exposure on future resistance, to apply it to
specific locations and time periods.

In conclusion, our findings have implications for both guidelines and clinical practice, and
methodological approaches to the epidemiology of antibiotic resistance. Clinically, our results
provide causal estimates of the additional risk and NNH impacted by prior use of penicillins and
quinolones in the outpatient settings, over different periods since exposure. Such estimates should
also play a substantial role in the cost-benefit considerations when determining empiric antibiotic
treatment guidelines. Specifically, penicillins induce substantial future resistance to
amoxicillin/clavulanic acid, ampicillin, and to a lower extent piperacillin tazobactam. Moreover,
penicillins, compared to quinolones, appear to induce lower respective AMR, thereby enhancing
their utility in subsequent treatments. Methodologically, we propose a novel approach, built on an
original IV, that opens a venue for further research on antibiotic groups inducing allergic reactions,
such as cephalosporins, fluoroquinolones, and sulfonamides.

Methods
This research received IRB approval from Maccabi Healthcare Services (MHS) under protocol
number MHS-0036-23.

Data

Maccabi Healthcare Services (MHS), the second-largest non-profit health fund in Israel, covers
26.7% of the population (~2.7 million in 2022) nationwide, with less than 1% disengagement.
Membership in one of the four health funds is mandatory and non-excludable. MHS maintains a
long-term centralized database of electronic medical records (EMRs), including extensive
demographic and clinical data from both outpatients and hospitals.

Study design

In this retrospective cohort study, data were collected on adult members (aged≥18 years) of MHS
who purchased antibiotics in primary care between January 1, 2013, and December 31, 2022.

Individuals were eligible to contribute multiple entries to the study within the specified timeframe,

provided they had not purchased antibiotics within 12 months prior to the entry date or been

hospitalized for at least one night during the same period.

The exposed group consisted of all penicillin-group antibiotic purchases, while the control groups

included purchases from the following antibiotic families: cephalosporins, macrolides,

trimethoprim-sulfamethoxazole, quinolones, tetracyclines, fosfomycin, nitrofurantoin,

aminoglycosides, and other beta-lactam antibiotics (Table 1).

The exposures to penicillins were comprised of 46% amoxicillin, 39% amoxicillin/clavulanic acid,

and the remaining 15% of other penicillin derivatives. Although these antibiotics may serve to

treat different indications, there is also substantial overlap between their targets and therefore

physicians may sometimes prescribe them interchangeably[3].

For both groups, the index date was set as the date of antibiotic purchase, and individuals were

followed until either a positive urine culture test that prompted an AMR test (the outcome) or

patient exclusion occurred. Censoring, in the sense of excluding the follow-up of patients to

observe their outcomes, was applied in cases of subsequent antibiotic use, hospitalization, death,

or reaching the conclusion of the follow-up period, which extended until 365 days after the index

date or until December 31, 2022 - whichever came first. Potential selection bias due to such

censoring was addressed using IPCW, as described below.

We excluded cases where more than one antibiotic family had been purchased to negate the

influence of other antibiotic exposures. Furthermore, we excluded individuals residing in nursing

homes and those who were homebound to mitigate potential confounding attributable to

healthcare-associated infections or distinct prescription practices prevalent outside of primary care

settings. This study design permitted the inclusion of multiple AMR tests for a single entry, if the

specified exclusion and censoring criteria were fulfilled.

Procedures

Individual-level demographic data for the study population included sex, age at the index date,

socio-economic status, and social sector indication. The socioeconomic status of residential areas

was assessed using coded Geographical Statistical Areas (GSAs), the smallest units recognized by

the Israeli census. Assigned by Israel's Central Bureau of Statistics, these GSAs are rated on a

scale from 1 (lowest) to 10, based on multiple parameters. Data on chronic conditions were

obtained from MHS' automated registries, covering cardiovascular diseases [26], hypertension [27],
diabetes[28], chronic kidney disease (CKD)[29], and immunocompromised states. We identified
penicillin allergy using two complementary sources: ICD-9 diagnosis codes (V14.0) and
physician-documented mentions of allergy in the free-text sections of medical records. While free-
text documentation was available only for cases already flagged with ICD-9 codes, no instances
were observed where a free-text note indicated a penicillin allergy without a corresponding
diagnosis code. Importantly, the observed prevalence of penicillin allergy in our cohort (8.5%)
aligns well with the 8–12% prevalence reported in the literature[25,30,31], supporting the validity of
our identification methods.
In Israel, the procurement of antibiotics is strictly regulated, requiring a prescription for purchase
and all transactions related to the acquisition of antibiotics by members of MHS to be
systematically recorded and digitized within the EMR system.
289
Outcomes

Our outcomes were the binary results of antibiotic susceptibility tests, with resistance coded as 1,
at various follow-up times (90, 180, 270, and 365 days). We considered antibiotic resistance results
within the penicillin group, comprising ampicillin, amoxicillin clavulanic acid and
piperacillin/tazobactam, as well as ciprofloxacin within the fluoroquinolones group. We note that
piperacillin/tazobactam was added as a penicillin-group outcome but not exposure, because
susceptibility to it is routinely tested, while it is very rarely prescribed in the community settings,
in Israel. Gentamicin, an aminoglycoside antibiotic, served as an NCO for the IV independence
assumption [15,16](explained below). We chose gentamicin due to its lack of association with the
penicillin/beta-lactam family, its relative frequency in AMR test panels, and its infrequent use in
outpatient settings. The bacterial identification and antibiotic susceptibility testing were conducted
using the automated VITEK 2 system, following Clinical and Laboratory Standards Institute
guidelines. Intermediate results were considered as resistant.
Our analysis focused exclusively on *Escherichia coli* isolates, which accounted for 71.6% of the
total samples. Utilizing IV analysis, we estimated the risk difference of antibiotic resistance
between individuals exposed to penicillins and those exposed to alternative antibiotic groups at
the various post-antibiotic use follow-up times.

 IV framework

We assert that antibiotic allergies, particularly penicillin[25], can serve as an IV in studying antibiotic

use and future AMR. Although often self-reported, misdiagnosed, or resolved[32], perceived

allergies influence physicians' treatment choices, meeting the conditions for a valid IV.

To be valid, IVs need to fulfill three essential conditions [12]. The first, known as the Relevance

condition, stipulates that the IV must be associated with exposure. The second, the Exclusion

Restriction condition, asserts that the IV's impact on the outcome occurs exclusively through

exposure, and not via alternative paths. The third, referred to as the Independence condition,

requires that the association between the IV and the outcome is not confounded by external factors.

Provided that the linear model specification employed for estimation is valid, and under the

assumption of a homogeneous treatment effect across the population, these conditions enable the

identification and consistent estimation of the average treatment effect (ATE)[33].

Statistical Methods

We estimated the RD using Two Stage least squares (2SLS) regression[33–35]. To uphold the

Independence condition, the estimation was adjusted for potential confounders of the IV (allergy

to penicillin) and the outcome (AMR) association, including sex, age, socio-economic status,

social sector, calendar time, and comorbidities such as diabetes mellitus (DM), chronic kidney

disease (CKD), immunosuppression, hypertension and cardiovascular diseases. To address the

potential influence of healthcare-seeking behavior on both penicillin allergy reporting and AMR,

we used proxies like the count of previous antibiotic purchases and urine culture tests, adjusting

for these variables in the model. All continuous variables were modeled using restricted cubic

splines with five knots[36]. Potential confounders were measured at baseline. A DAG depicting the

assumed causal relationships between penicillin allergy, AMR, and other relevant covariates is

presented in Figure S2. Model diagnostics showed adequate fit, with all instrument coefficients

and fitted values within the expected range of [0,1]. To evaluate the relevance condition, we used

a *first-stage* ordinary least squares (OLS) regression, modeling the exposure as a function of the

IV and confounding covariates. The condition's validity was confirmed by examining the IV

coefficient and Kleibergen-Paap F-statistics. The exposure variable, indicating the purchase of a

penicillin antibiotic, was coded as binary. To maintain consistent directionality, the IV for

penicillin allergy was coded as '1' for non-allergic and '0' for allergic individuals.

Finally, selection bias may be introduced into the study as not all individuals are subjected to

resistance testing after a positive urine culture, and those who do may not be provided with relevant

antibiotic panels. To address this potential bias and account for interdependent observations, we

calculated 95% confidence intervals (CIs) using bootstrap resampling at the individual level, with

sampling weights proportionally applied to the IPCW[37]. IPCW compensates for censored patients

by giving more weight to similar non-censored patients, thus increasing their representation. The

weights were obtained from a logistic regression model that estimated the likelihood of undergoing

AMR testing. The model was adjusted for sex, age, socio-economic status, social sector, antibiotic

group, calendar time, and comorbidities (CKD, immunosuppression, and cardiovascular diseases).

Censoring probabilities and their distribution are in Table S6. Due to potential temporal variations

in IPCW weights, which were time-dependent and varied across entries for individuals with

multiple contributions, we used the average of these weights at the individual level in the bootstrap

procedure.

Data were extracted from the MHS database using Microsoft SQL Server 14. All statistical

analyses were performed in R version 3.6.2, and the ivtools package was used to estimate the

instrumental variable (IV) models.

References

1. Talebi Bezmin Abadi, A., Rizvanov, A. A., Haertlé, T. & Blatt, N. L. World Health

Organization Report: Current Crisis of Antibiotic Resistance. *BioNanoScience* **9**, 778–788

(2019).

2. Lesho, E. P. & Laguio-Vila, M. The Slow-Motion Catastrophe of Antimicrobial Resistance

and Practical Interventions for All Prescribers. *Mayo Clin. Proc.* **94**, 1040–1047 (2019).

3. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. (Elsevier,

Philadelphia, PA, 2020).

4. Lipsitch, M. & Samore, M. H. Antimicrobial Use and Antimicrobial Resistance: A Population

Perspective. *Emerg. Infect. Dis.* **8**, 347–354 (2002).

5. Chatterjee, A. *et al.* Quantifying drivers of antibiotic resistance in humans: a systematic

review. *Lancet Infect. Dis.* **18**, e368–e378 (2018).

6. De Nies, L., Kobras, C. M. & Stracy, M. Antibiotic-induced collateral damage to the

microbiota and associated infections. *Nat. Rev. Microbiol.* **21**, 789–804 (2023).

7. Bush, N. G., Diez-Santos, I., Abbott, L. R. & Maxwell, A. Quinolones: Mechanism, Lethality

and Their Contributions to Antibiotic Resistance. *Molecules* **25**, 5662 (2020).

8. Weiss, E. *et al.* Elaboration of a consensual definition of de-escalation allowing a ranking of

β-lactams. *Clin. Microbiol. Infect.* **21**, 649.e1-649.e10 (2015).

9. Madaras-Kelly, K. *et al.* Development of an Antibiotic Spectrum Score Based on Veterans

Affairs Culture and Susceptibility Data for the Purpose of Measuring Antibiotic De-

Escalation: A Modified Delphi Approach. *Infect. Control Hosp. Epidemiol.* **35**, 1103–1113

(2014).

10.   World Health Organization. *The Selection and Use of Essential Medicines: Report of the*

WHO Expert Committee, 2017 (Including the 20th WHO Model List of Essential Medicines

and the 6th Model List of Essential Medicines for Children). (World Health Organization,

Geneva, 2017).

11.   Chowers, M. *et al.* Estimating the impact of cefuroxime versus cefazolin and

amoxicillin/clavulanate use on future collateral resistance: a retrospective comparison. *J.*

Antimicrob. Chemother. **77**, 1992–1995 (2022).

12.   Angrist, J. D., Imbens, G. W. & Rubin, D. B. Identification of Causal Effects Using

Instrumental Variables. *J. Am. Stat. Assoc.* **91**, 444–455 (1996).

13.   Lipsitch, M., Tchetgen Tchetgen, E. & Cohen, T. Negative Controls: A Tool for

Detecting Confounding and Bias in Observational Studies. *Epidemiology* **21**, 383–388 (2010).

14.   Centers for Disease Control and Prevention. *Adult Outpatient Treatment*

Recommendations. https://www.cdc.gov/antibiotic-use/clinicians/adult-treatment-rec.html.

15.   Shi, X., Miao, W. & Tchetgen, E. T. A Selective Review of Negative Control Methods in

Epidemiology. *Curr. Epidemiol. Rep.* **7**, 190–202 (2020).

16.   Danieli, O., Nevo, D., Walk, I., Weinstein, B. & Zeltzer, D. Negative Controls for

Instrumental Variable Designs. (2023) doi:10.48550/ARXIV.2312.15624.

17.   Greenland, S., Pearl, J. & Robins, J. M. Causal Diagrams for Epidemiologic Research.

Epidemiology **10**, (1999).

18.   Baraz, A., Chowers, M., Nevo, D. & Obolski, U. The time-varying association between

previous antibiotic use and antibiotic resistance. *Clin. Microbiol. Infect.* **29**, 390.e1-390.e4

(2023).

19.   Hansen, B. B. Full Matching in an Observational Study of Coaching for the SAT. *J. Am.*

Stat. Assoc. **99**, 609–618 (2004).

20.   Austin, P. C. & Stuart, E. A. Optimal full matching for survival outcomes: a method that

merits more widespread use. *Stat. Med.* **34**, 3949–3967 (2015).

21.   Wooldridge, J. M. *Econometric Analysis of Cross Section and Panel Data*. (MIT Press,

406   Cambridge, Mass, 2010).

407   22.   Cherny, S. S. *et al.* Revealing antibiotic cross-resistance patterns in hospitalized patients

408   through Bayesian network modelling. *J. Antimicrob. Chemother.* **76**, 239–248 (2021).

409   23.   Cherny, S. S., Chowers, M. & Obolski, U. Bayesian network modeling of patterns of

410   antibiotic cross-resistance by bacterial sample source. *Commun. Med.* **3**, 61 (2023).

411   24.   Gottesman, B. S., Carmeli, Y., Shitrit, P. & Chowers, M. Impact of Quinolone Restriction

412   on Resistance Patterns of *Escherichia coli* Isolated from Urine by Culture in a Community

413   Setting. *Clin. Infect. Dis.* **49**, 869–875 (2009).

414   25.   Albin, S. & Agarwal, S. Prevalence and characteristics of reported penicillin allergy in an

415   urban outpatient adult population. *Allergy Asthma Proc.* **35**, 489–494 (2014).

416   26.   Shalev, V. *et al.* The use of an automated patient registry to manage and monitor

417   cardiovascular conditions and related outcomes in a large health organization. *Int. J. Cardiol.*

418   **152**, 345–349 (2011).

419   27.   Weitzman, D., Chodick, G., Shalev, V., Grossman, C. & Grossman, E. Prevalence and

420   Factors Associated With Resistant Hypertension in a Large Health Maintenance Organization

421   in Israel. *Hypertension* **64**, 501–507 (2014).

422   28.   Chodick, G., Heymann, A. D., Shalev, V. & Kookia, E. The epidemiology of diabetes in

423   a large Israeli HMO. *Eur. J. Epidemiol.* **18**, 1143–1146 (2002).

424   29.   Coresh, J. *et al.* Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of

425   End-Stage Renal Disease and Mortality. *JAMA* **311**, 2518 (2014).

30.   Macy, E. Penicillin and Beta-Lactam Allergy: Epidemiology and Diagnosis. *Curr.*

Allergy Asthma Rep. **14**, 476 (2014).

31.   Trubiano, J. A. *et al.* The prevalence and impact of antimicrobial allergies and adverse

drug reactions at an Australian tertiary centre. *BMC Infect. Dis.* **15**, 572 (2015).

32.   Stone, C. A., Trubiano, J., Coleman, D. T., Rukasin, C. R. F. & Phillips, E. J. The

challenge of de-labeling penicillin allergy. *Allergy* **75**, 273–288 (2020).

33.   Angrist, J. D. & Pischke, J.-S. *Mostly Harmless Econometrics: An Empiricist's*

Companion. (Princeton University Press, Princeton, 2009).

34.   Brookhart, M. A., Wang, P. S., Solomon, D. H. & Schneeweiss, S. Evaluating Short-

Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental

Variable: *Epidemiology* **17**, 268–275 (2006).

35.   Wang, P. S. *et al.* Risk of Death in Elderly Users of Conventional vs. Atypical

Antipsychotic Medications. *N. Engl. J. Med.* **353**, 2335–2341 (2005).

36.   Harrell, F. E. in *Regression modeling strategies: with applications to linear models,*

logistic and ordinal regression, and survival analysis 24–28 (Springer, Cham Heidelberg New

York, 2015).

37.   Howe, C. J., Cole, S. R., Lau, B., Napravnik, S. & Eron, J. J. Selection Bias Due to Loss

to Follow Up in Cohort Studies: *Epidemiology* **27**, 91–97 (2016).

Data Availability

According to the Israel Ministry of Health regulations, individual-level data cannot be shared openly. Specific requests for remote access to de-identified community-level data should be referred to KSM, Maccabi Healthcare Services Research and Innovation Center.

Code Availability

The source code is available at https://github.com/yakiSaciuk/Estimating-Penic-AMR-using-IV. The repository contains R scripts for estimating risk differences (RD) using two-stage least squares (2SLS) instrumental variable analysis, deriving confidence intervals via bootstrap sampling, while applying inverse probability of censoring weights (IPCW). The code is provided under the MIT License.

Acknowledgements

This work was supported by the Israel Science Foundation (ISF 1286/21) - UO

Author Contributions Statement

Conceptualization: YS, UO
Methodology: YS, DN, UO
Investigation: YS, MC, UO
Visualization: YS
Funding acquisition: UO
Supervision: UO
Writing – original draft: YS, MC
Writing – review & editing: DN, MC, UO

Competing Interests Statement

The authors have no competing interests to declare.

485 **Tables**

487 **Table 1:** Characteristics of the Primary Research Population at First Eligible Antibiotic Use

488 (2013-2022), stratified by reported Penicillin Allergy.

	Allergy to Penicillin			
	No *(N=1,343,852)*	Yes *(N=125,772)*	Overall *(N=1,469,624)*	SMD
Sex (Female) N (%)	721,862 (53.7%)	85,394 (67.9%)	80,7256 (54.9%)	0.29
Age				
Mean (SD)	41.6 (16.8)	47.1 (17.5)	42.1 (16.9)	0.32
SES N (%)				0.17
High	464,569 (34.6%)	49,845 (39.6%)	514,414 (35.0%)	
Low	274,338 (20.4%)	18,085 (14.4%)	292,423 (19.9%)	
Middle	603,042 (44.9%)	57,674 (45.9%)	660,716 (45.0%)	
Unknown	1,903 (0.1%)	168 (0.1%)	2,071 (0.1%)	
Social Sector N (%)				0.21
General Population	1,151,436 (85.7%)	115,264 (91.6%)	1,266,700 (86.2%)	
Orthodox Jews	103,401 (7.7%)	6,994 (5.6%)	110,395 (7.5%)	
Arabs	89,015 (6.6%)	3,514 (2.8%)	92,529 (6.3%)	
Calendar year				
Mean (SD)	2,016.39 (2.83)	2,015.82 (2.61)	2,016.43(2.83)	0.20
Antibiotic Group N (%)				0.96
Penicillins	768,956 (57.2%)	22,713 (18.1%)	791,669 (53.9%)	
Cephalosporins	178,390 (13.3%)	23,085 (18.4%)	201,475 (13.7%)	
Other beta lactams	18 (0.0%)	2 (0.0%)	20 (0.0%)	
Macrolides	161,962 (12.1%)	50,325 (40.0%)	212,287 (14.4%)	
Quinolones	109,917 (8.2%)	14,797 (11.8%)	124,714 (8.5%)	
Tetracyclines	59,467 (4.4%)	6,936 (5.5%)	66,403 (4.5%)	
Fosfomycin Trometamol	37,314 (2.8%)	3,941 (3.1%)	41,255 (2.8%)	
Trimethoprim/sulfamethoxazole	10,801 (0.8%)	1,655 (1.3%)	12,456 (0.8%)	
Nitrofurantoin	16,952 (1.3%)	2,313 (1.8%)	19,265 (1.3%)	
Aminoglycoside	75 (0.0%)	5 (0.0%)	80 (0.0%)	
Cardiovascular disease (Yes) N (%)	74,107 (5.5%)	10,139 (8.1%)	84,246 (5.7%)	0.10
Chronic kidney disease (CKD) (1) N (%)				0.18
G1	1,242,715 (92.5%)	109,589 (87.1%)	1,352,304 (92.0%)	
G2	11,234 (0.8%)	1,333 (1.1%)	12,567 (0.9%)	
G3a	5,144 (0.4%)	657 (0.5%)	5,801 (0.4%)	
G3b	80,632 (6.0%)	13,522 (10.8%)	94,154 (6.4%)	
G4	3,037 (0.2%)	525 (0.4%)	3,562 (0.2%)	
G5	1,090 (0.1%)	146 (0.1%)	1,236 (0.1%)	
Diabetes Mellitus (Yes) N (%)	88,744 (6.6%)	11,681 (9.3%)	100,425 (6.8%)	0.10
Hypertension (Yes) N (%)	202,485 (15.1%)	28,098 (22.3%)	230,583 (15.7%)	0.19
Immunosuppressed (Yes) N (%)	37,839 (2.8%)	5,791 (4.6%)	43,630 (3.0%)	0.10

(1)   Stages of CKD are classified based on estimated glomerular filtration rate (eGFR). G1: >90 ml/min, G2: 60 to 89 ml/min, G3a: 45 to 59 ml/min, G3b: 30 to 44 ml/min, G4: 15 to 29 ml/min, G5: <15 ml/min

Table 2: Instrumental Variable (IV)-Estimated Risk Differences of Antimicrobial Resistance (AMR) Rates: A Comparison between Exposure to Penicillins and Other Antibiotics Across Varying Time Points Post-Exposure.

| AMR Antibiotic | Follow up length | Number of AMR Tests | RD IV (1)(2) | 95% C.I. (1)(2) | | NNH |
				Lower Bound (2.5%)	Upper Bound (97.5%)	
Amoxicillin/clavulanic acid	Up to: 90 days	7,502	19.0%	11.8%	26.1%	5.3
	Up to: 180 days	12,393	14.9%	9.9%	20.2%	6.7
	Up to: 270 days	16,027	11.9%	7.8%	16.1%	8.4
	Up to: 365 days	18,797	11.4%	7.6%	15.4%	8.8
Ampicillin	Up to: 90 days	13,776	22.6%	14.6%	31.0%	4.4
	Up to: 180 days	21,828	18.2%	11.9%	24.6%	5.5
	Up to: 270 days	27,587	15.9%	10.1%	21.2%	6.3
	Up to: 365 days	32,006	14.1%	9.0%	19.4%	7.1
Piperacillin/ Tazobactam	Up to: 90 days	15,203	2.5%	1.4%	3.5%	40.2
	Up to: 180 days	24,639	1.6%	0.9%	2.2%	61.7
	Up to: 270 days	31,730	1.1%	0.4%	1.7%	87.7
	Up to: 365 days	37,295	0.8%	0.2%	1.4%	122.0
Gentamicin (Negative Control)	Up to: 90 days	17346	-2.3%	-6.5%	1.4%	-43.5*
	Up to: 180 days	27824	-1.5%	-4.5%	1.3%	-66.2*
	Up to: 270 days	35447	-1.3%	-3.8%	0.8%	-79.4*
	Up to: 365 days	41317	-0.2%	-2.4%	1.8%	-500.0*

(1) Weighted with inverse probability of censoring weights (IPCW)
(2) Adjusted for sex, age, ses, social sector, comorbidities (CKD, cardio-vascular disease, diabetes mellitus, hypertension and immunosuppression), calendar time, previous urine culture tests count, and pervious antibiotic uses count
* The negative NNH is interpreted as the absolute value of the NNH when switching the penicillins to be the comparator group.

Table 3: Instrumental Variable (IV)-Estimated Risk Differences of Antimicrobial Resistance (AMR): Direct Comparison of Penicillin vs. Quinolones Within 180 Days Post-Exposure

| AMR Antibiotic | Number of AMR Tests | RD IV (1)(2) | 95 % C.I.(1)(2) | | NNH |
			Lower Bound (2.5%)	Upper Bound (97.5%)	
Amoxicillin/clavulanic acid	4,918	17.8%	2.1%	35.2%	5.6
Ampicillin	10,003	8.0%	-5.3%	22.6%	12.4
Piperacillin/Tazobactam	10,564	2.8%	0.9%	4.6%	35.3
Gentamicin (Negative Control)	12,291	-5.4%	-14.6%	2.8%	-18.7*
Ciprofloxacin (Quinolone)	11,073	-43.9%	-59.4%	-29.9%	-2.3*

(1) Weighted with inverse probability of censoring weights (IPCW)
(2) Adjusted for sex, age, ses, social sector, comorbidities (ckd, cardio-vascular disease, diabetes mellitus, hypertension and immunosuppression), calendar time, previous urine culture tests count, and pervious antibiotic uses count
* The negative NNH is interpreted as the absolute value of the NNH when switching the penicillins to be the comparator group.

Figure Legends/Captions (for main text figures)

Figure 1: Causal relations in the instrumental variable (IV) framework can be depicted using Directed Acyclic Graphs (DAGs). The interest lies in determining the effect of the exposure (X) on the outcome (Y). This effect may not be identifiable—i.e., causally estimable—in the presence of unmeasured confounders (U_1). However, employing a valid IV (Z) may enable the identification of this effect. First, Z must influence the exposure X, a condition known as the Relevance condition. Furthermore, Z should affect Y solely through X—a condition termed Exclusion Restriction. Measured confounders (C) and unmeasured variables (U) may impact Z, X and Y, potentially confounding their association. Adjusting for C blocks the $Z <- C -> Y$ path, strengthening the third requirement—the Independence condition. However, the presence of an unmeasured variable (U_2)

could still compromise this condition and hinder the identification of the causal effect of *X* on *Y*.

Dashed and dotted lines represent violations of the Exclusion Restriction and Independence

conditions, respectively. A negative control outcome (*N*) should share a similar set of measured

common causes (*C*) with *Y* and *Z*. If the unobserved common causes of *Z* and *Y* overlap with those

of *Z* and *N* (U_2), then *N* is considered *U-comparable* to *Y*. Hence, if the independence condition is

met, we would naturally expect *Z* to not be associated with *N*, when adjusting for *C*.

Y - Outcome -AMR
X -Exposure - Use of penicillin vs other antibiotic groups
C- Measured Confounder(s)
Z - Instrumental Variable(IV) - Allergy to penicillin
Ui - Unmeasured Variables(s)
N - Negative Control Outcome

611
612 **Figure 2:** Study population flow chart.
613

1,626,755 MHS covered members age 18 and above for whom 10,256,609 prescriptions were dispensed in outpatient settings between 2013 and 2022

50,854 MHS covered members, either elderly care home residents or homebound individuals, for whom 494,007 prescriptions were dispensed, were excluded.

A total of 6,209,180 prescriptions, which followed an earlier antibiotic dispensation within the preceding 12 months, were excluded from the analysis.

A total of 284,219 prescriptions, dispensed within a 12-month period following a hospitalization of at least one night's duration, were excluded from the analysis.

A total of 163,112 prescriptions, containing multiple classes of antibiotics, were excluded from the analysis.

Primary study population: 1,469,624 MHS covered members with 3,106,091 prescriptions dispensed in outpatient settings

36,351 MHS covered members with 38,648 instances of antibiotic use had 41,647 AMR assessments conducted within 12 months post-exposure

17,238 MHS covered members with 17,740 instances of antibiotic use underwent 18,797 Amoxicillin/clavulanic acid AMR tests.

28,479 MHS covered members with 29,903 instances of antibiotic use underwent 32,006 Ampicillin AMR tests.

32,867 MHS covered members with 34,739 instances of antibiotic use underwent 37,295 Piperacillin/Tazobactam AMR tests.

36,119 MHS covered members with 38,371 instances of antibiotic use underwent 41,317 Gentamicin AMR tests.

32,985 MHS covered members with 34,889 instances of antibiotic use underwent 37,516 Ciprofloxacin AMR tests.

614
615
616

Figure 3: Instrumental Variable (IV)-Estimated Risk Differences for Antimicrobial Resistance (AMR) Over Time Post-Exposure to Penicillins Compared to Other Antibiotics. AMR outcomes include: (a) amoxicillin/clavulanic acid (n=18,797 tests), (b) ampicillin (n=32,006 tests), (c) piperacillin/tazobactam (n=37,295 tests), and (d) gentamicin (n=41,317 tests). Bars represent 95% confidence intervals (CIs) around the mean risk differences, derived from bootstrap sampling (3,000 iterations). The x-axis displays the number of days following exposure to penicillins. Risk differences compare resistance outcomes following exposure to penicillins versus other antibiotics. Detailed numerical values, including risk differences and corresponding confidence intervals, are provided in Table 2

Figure 4: Instrumental Variable (IV)-Estimated Risk Differences for Antimicrobial Resistance

(AMR) Between Penicillins and Quinolones Within 180 Days After Exposure. Bars represent 95%

confidence intervals (CIs) derived from bootstrap sampling (3,000 iterations. The x-axis displays

the tested AMR outcomes, which include: amoxicillin/clavulanic acid (n=4,918 tests), ampicillin

(n=10,003 tests), piperacillin/tazobactam (n=10,564 tests), gentamicin (n=12,291 tests), and

ciprofloxacin (n=11,073 tests). Risk differences compare resistance outcomes following exposure

to penicillins versus quinolones. Detailed numerical values, including risk differences and

corresponding confidence intervals, are provided in Table 3.